P11 - Aggressive Variants of Prostate Cancer: Mechanisms of Transdifferentiation, Development of Resistance and Treatment Optimization

presented by

Gunhild von Amsberg
Department of Internal Medicine II (Oncology Center), University Medical Center Hamburg-Eppendorf ; Martini-Klinik at the University Medical Center Hamburg-Eppendorf

Tumor samples of patients suffering from aggressive variants of prostate cancer (AVPC) are sequenced and alterations in the known tumor promoters and tumor-suppressor genes are identified. Investigation of the effects of combined gene alterations on the tumor cells growth, survival and therapy resistance are currently investigated to identify new incites in aggressive transformation ultimately leading to treatment resistance. To better understand the single steps contributing to aggressive transdifferentation multi-OMICS approaches (proteomics, transcriptomics and kinomics) are applied in prostate cancer cells exposed to long-term drug treatment (Dyshlovoy et al., Oncol Res Treatment, 2021).In this context, novel platine-based drug combinations have been examined retrospectively in patients suffering from AVPC or advanced PCa resistant to new hormonal agents and docetaxel chemotherapy. In vitro analyses help to reveal the activity of the individual drugs in classical adenocarcinoma and AVPC. (von Amsberg G., et al. J Clin Oncol, 2021).

Contact: g.von-amsberg@uke.de

  • Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer. von Amsberg G, Zilles M, Mansour W, Gild P, Alsdorf W, Kaune M, Böckelmann L, Hauschild J, Krisp C, Rohlfing T, Saygi C, Alawi M, Zielinski A, Langebrake C, Oh-Hohenhorst SJ, Perner S, Tilki D, Schlüter H, Graefen M, Dyshlovoy SA, Bokemeyer C. Int J Mol Sci. 2022 Nov 29;23(23):14948. doi: 10.3390/ijms232314948.PMID: 36499277

    Long-term taxane-exposure favors neuroendocrine transdifferentation of prostate cancer in vitro. Dyshlovoy S., Hauschild J., Krisp C., Schlüter H., Bokemeyer C., Graefen M., von Amsberg G. Oncol Res Treat 2021;44(suppl 4):1–329